AKAP8 is a multifunctional scaffolding protein that anchors protein kinase A (PKA) to specific cellular compartments, thereby organizing cAMP-dependent signaling complexes. Beyond its canonical PKA-anchoring role, AKAP8 regulates mitotic chromosome 19 by recruiting the condensin complex and histone deacetylase HDAC3 to chr19, facilitating histone H3 deacetylation during mitosis. AKAP8 also enhances histone methyltransferase activity of the KMT2 family complex MLL4, contributing to transcriptional regulation and developmental gene expression. At the molecular level, AKAP8 functions as an RNA-binding protein and splicing regulator; it antagonizes the epithelial-mesenchymal transition (EMT) by inhibiting the EMT-promoting splicing factor hnRNPM and directly modulating alternative splicing programs 1. Recent evidence suggests AKAP95 (an AKAP8 orthologue) regulates cancer through formation of biomolecular condensates that control transcription and can be targeted therapeutically in MLL-fusion driven leukemia 2. Clinically, AKAP8 and AKAP8L gene dosage at chromosome 19.12 correlates strongly with head size variation and autism risk 3, and AKAP8 expression predicts breast cancer survival 1. In colon cancer, AKAP95 participates in ERK1/2-Elk-1 signal transduction and correlates with immune infiltration and poor prognosis 4. Disruption of AKAP95 condensate properties impairs its splicing regulatory activity and tumor-promoting functions, suggesting condensate-modifying peptides represent a therapeutic approach 2.